Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules

Diagnostic Pathology

Volumn 5, Issue 1, 2010, Pages

  Saleh, Husain A ^a   Jin, Bo ^a   Barnwell, John ^b   Alzohaili, Opada ^c  

^a WAYNE STATE UNIVERSITY   (United States)

^b DETROIT MEDICAL CENTER   (United States)

^c SINAI GRACE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 19; GALECTIN 3; HBME 1 ANTIGEN; HBME-1 ANTIGEN; PROTEIN RET; RET PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CHEMISTRY; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; EVALUATION; HUMAN; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; PATHOLOGY; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; THYROID NODULE; THYROID TUMOR;

DIAGNOSIS, DIFFERENTIAL; GALECTIN 3; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; KERATIN-19; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-RET; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; THYROID NODULE; TUMOR MARKERS, BIOLOGICAL;

EID: 77649327299     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-5-9     Document Type: Article

References (35)

1. Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions. Oestreicher-Kedem Y, Halpern M, Roizman P, Hardy B, Sulkes J, Feinmesser R, Stern Y, Head Neck 2004 26 11 960 6 10.1002/hed.20087 15386597 (Pubitemid 39488123)
2. Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Papotti M, Rodriguez J, De Pompa R, Bartolazzi A, Rosai J, Mod Pathol 2005 18 4 541 6 10.1038/modpathol.3800321 15529186 (Pubitemid 40478118)
3. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT, Mod Pathol 2005 18 1 48 57 10.1038/modpathol.3800235 15272279 (Pubitemid 40128094)
4. Papillary thyroid carcinoma: a root-and-branch rethink. Rosai J, Am J Clin Pathol 2008 130 5 683 6 10.1309/AJCPBF63BWMCYSLW 18854259
5. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. Sahoo S, Hoda SA, Rosai J, DeLellis RA, Am J Clin Pathol 2001 116 5 696 702 10.1309/6D9D-7JCM-X4T5-NNJY 11710686 (Pubitemid 34453210)
6. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Weber KB, Shroyer KR, Heinz DE, Nawaz S, Said MS, Haugen BR, Am J Clin Pathol 2004 122 4 524 31 10.1309/ UUQTE505PTN5QJ7M 15487449 (Pubitemid 39281248)
7. Diagnostic utility of galectin-3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules. Aratake Y, Umeki K, Kiyoyama K, Hinoura Y, Sato S, Ohno A, Kuribayashi T, Hirai K, Nabeshima K, Kotani T, Diagn Cytopathol 2002 26 6 366 72 10.1002/dc.10111 12112826 (Pubitemid 34596007)
8. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, Inohara H, Marandino F, Orlandi F, Nardi F, others, Lancet 2001 357 9269 1644 50 10.1016/S0140-6736(00)04817-0 11425367 (Pubitemid 32568236)
9. Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Barroeta JE, Baloch ZW, Lal P, Pasha TL, Zhang PJ, LiVolsi VA, Endocr Pathol 2006 17 3 225 34 10.1385/EP:17:3:225 17308359 (Pubitemid 46279670)
10. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Beesley MF, McLaren KM, Histopathology 2002 41 3 236 43 10.1046/j.1365-2559.2002.01442.x 12207785 (Pubitemid 35013945)
11. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Casey MB, Lohse CM, Lloyd RV, Endocr Pathol 2003 14 1 55 60 10.1385/EP:14:1:55 12746563 (Pubitemid 36605683)
12. Immunohistochemical diagnosis of papillary thyroid carcinoma. Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL, Mod Pathol 2001 14 4 338 42 10.1038/modpathol.3880312 11301350 (Pubitemid 32298919)
13. Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. El Demellawy D, Nasr A, Alowami S, Diagn Pathol 2008 3 5 10.1186/1746-1596-3-5 18254952
14. Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Herrmann ME, LiVolsi VA, Pasha TL, Roberts SA, Wojcik EM, Baloch ZW, Arch Pathol Lab Med 2002 126 6 710 3 12033961 (Pubitemid 34602574)
15. The investigation of galectin-3 in diseases of the thyroid gland. Kovacs RB, Foldes J, Winkler G, Bodo M, Sapi Z, Eur J Endocrinol 2003 149 5 449 53 10.1530/eje.0.1490449 14585093 (Pubitemid 37461528)
16. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Scognamiglio T, Hyjek E, Kao J, Chen YT, Am J Clin Pathol 2006 126 5 700 8 10.1309/044V86JN2W3CN5YB 17050067 (Pubitemid 44707620)
17. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms. Aron M, Kapila K, Verma K, Indian J Pathol Microbiol 2006 49 3 376 80 17001889 (Pubitemid 44422282)
18. Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples. Collet JF, Hurbain I, Prengel C, Utzmann O, Scetbon F, Bernaudin JF, Fajac A, Br J Cancer 2005 93 10 1175 81 10.1038/sj.bjc.6602822 16251880 (Pubitemid 41670703)
19. Differential expression of galectin-3 in papillary projections of malignant and non-malignant hyperplastic thyroid lesions. Cvejic D, Savin S, Petrovic I, Paunovic I, Tatic S, Havelka M, Acta Chir Iugosl 2003 50 3 67 70 10.2298/ACI0303067C 15179758
20. Expression of galectin-3 in normal and malignant thyroid tissue by quantitative PCR and immunohistochemistry. Feilchenfeldt J, Totsch M, Sheu SY, Robert J, Spiliopoulos A, Frilling A, Schmid KW, Meier CA, Mod Pathol 2003 16 11 1117 23 10.1097/01.MP.0000096047.99202.31 14614051 (Pubitemid 37414206)
21. Diagnostic utility of galectin-3 in aspirates of thyroid follicular lesions. Kim MJ, Kim HJ, Hong SJ, Shong YK, Gong G, Acta Cytol 2006 50 1 28 34 16514837 (Pubitemid 43157428)
22. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. Park YJ, Kwak SH, Kim DC, Kim H, Choe G, Park do J, Jang HC, Park SH, Cho BY, Park SY, J Korean Med Sci 2007 22 4 621 8 10.3346/jkms.2007.22. 4.621 17728499
23. [Significance of galectin-3 and CD44v6 expression in differential diagnosis of thyroid nodules]. Wang LH, Zhao YJ, Wang XY, Yuan P, Xu WQ, Xiao JC, Xu JP, Luo BR, Zhonghua Zhong Liu Za Zhi 2005 27 9 547 50 16438854
24. Discrimination of benign and malignant thyroid nodules by molecular profiling. Finley DJ, Zhu B, Barden CB, Fahey TJ, Ann Surg 2004 240 3 425 36 discussion 436-7 10.1097/01.sla.0000137128.64978.bc 15319714 (Pubitemid 39121337)
25. Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Elsheikh TM, Asa SL, Chan JK, DeLellis RA, Heffess CS, LiVolsi VA, Wenig BM, Am J Clin Pathol 2008 130 5 736 44 10.1309/AJCPKP2QUVN4RCCP 18854266
26. Thyroid disease classification. Bartolazzi A, Gasbarri A, Lancet 2000 356 9246 2010 1 10.1016/S0140-6736(05)72981-0 11130546
27. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas. Saggiorato E, Aversa S, Deandreis D, Arecco F, Mussa A, Puligheddu B, Cappia S, Conticello S, Papotti M, Orlandi F, J Endocrinol Invest 2004 27 4 311 7 15233548 (Pubitemid 38744608)
28. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HBME1 combined with CK19 immunostaining. Nasr MR, Mukhopadhyay S, Zhang S, Katzenstein AL, Mod Pathol 2006 19 12 1631 7 10.1038/modpathol.3800705 16998461 (Pubitemid 44789932)
29. [Galectin-3 immunodetection in thyroid fine-needle aspirates: technical procedure and results]. Collet JF, Fajac A, Ann Pathol 2006 26 5 347 51 17255922 (Pubitemid 46031712)
30. Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue. Cvejic D, Savin S, Paunovic I, Tatic S, Havelka M, Sinadinovic J, Anticancer Res 1998 18 4A 2637 41 9703921 (Pubitemid 28386560)
31. Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid. Erkilic S, Aydin A, Kocer NE, Endocr Pathol 2002 13 3 207 11 10.1385/EP:13:3:207 12446919 (Pubitemid 36021032)
32. Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma. Nakamura N, Erickson LA, Jin L, Kajita S, Zhang H, Qian X, Rumilla K, Lloyd RV, Endocr Pathol 2006 17 3 213 23 10.1385/EP:17:3:213 17308358 (Pubitemid 46279669)
33. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Rossi ED, Raffaelli M, Mule A, Miraglia A, Lombardi CP, Vecchio FM, Fadda G, Histopathology 2006 48 7 795 800 10.1111/j.1365-2559.2006.02428.x 16722927 (Pubitemid 43800938)
34. Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Bartolazzi A, Orlandi F, Saggiorato E, Volante M, Arecco F, Rossetto R, Palestini N, Ghigo E, Papotti M, Bussolati G, others, Lancet Oncol 2008 9 6 543 9 10.1016/S1470-2045(08)70132-3 18495537
35. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpcao LV, Metze K, Ward LS, Histopathology 2005 47 4 391 401 10.1111/j.1365-2559.2005.02221.x 16178894 (Pubitemid 41428488)